Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a pioneering United States-based biotechnology company dedicated to combating cancers and infectious diseases through DNA medicines. The company's innovative approach harnesses active DNA-based immunotherapies and vaccines to both treat and prevent these conditions.
Inovio's core technology revolves around its DNA plasmids, which are small circular DNA molecules crafted to produce specific proteins to target and fight diseases, delivered via their proprietary CELLECTRA® electroporation devices. This technology enables the body to produce its own disease-fighting proteins and immune responses, without the need for traditional adjuvants or nanoparticles.
The company's flagship candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease caused by HPV-6 and HPV-11. Inovio has shown significant clinical progress with INO-3107, and after receiving Breakthrough Therapy designation and Orphan Drug designation from both the FDA and the European Commission, it is on track to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. With successful clinical trials demonstrating a robust immune response and a reduction in the need for surgical interventions, INO-3107 stands as a potential game-changer for RRP patients.
In addition to INO-3107, Inovio's expansive product pipeline includes several other promising candidates in various stages of development. These include INO-3112 for HPV-16/18 positive head and neck cancer, INO-4201 as an Ebola vaccine booster, and INO-5401 for glioblastoma, showcasing the versatility and broad applicability of the company's DNA medicine platform.
Inovio has established numerous strategic partnerships and collaborations to enhance its research and development efforts. Key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program. These collaborations not only bolster Inovio's scientific capabilities but also facilitate the swift advancement of its clinical programs.
Financially, Inovio has maintained a disciplined approach to managing its resources. The company recently projected its cash runway to extend into the second quarter of 2025, following positive feedback from the FDA on the accelerated approval pathway for INO-3107. This financial stability is crucial as Inovio prepares for potential commercialization of its lead candidates.
Inovio's commitment to innovation and its effective strategic execution position it as a formidable player in the biopharmaceutical industry, dedicated to bringing groundbreaking DNA medicine solutions to market. For more information, visit www.inovio.com.
INOVIO (NASDAQ: INO) announced that an abstract for INO-3107, targeting Recurrent Respiratory Papillomatosis (RRP), has been accepted for oral presentation at the ABEA program during the COSM 2023 in Boston, scheduled for May 5, 2023. The presentation will showcase safety and immunogenicity data from both cohorts of a recently completed Phase 1/2 trial involving 32 RRP patients. RRP, primarily caused by HPV-6 and HPV-11, leads to the growth of benign warts in the respiratory tract but can cause serious complications. INO-3107 is a clinical-stage DNA medicine aimed at inducing T cell responses against these HPV types, potentially curbing papilloma growth. In July 2020, INO-3107 received Orphan Drug Designation from the FDA.
INOVIO (NASDAQ: INO) announced a positive opinion from the European Committee for Orphan Medicinal Products (COMP) regarding its application for orphan drug designation for INO-3107, intended for treating Recurrent Respiratory Papillomatosis (RRP). This rare disease, often caused by HPV types 6 and 11, leads to small growths in the respiratory tract, posing severe risks like airway obstruction. The European Commission is expected to make a final decision by late May 2023. Orphan designation is crucial for medicines targeting rare, life-threatening diseases affecting fewer than 5 in 10,000 individuals in the EU.
INOVIO (NASDAQ: INO) announced promising results from a Phase 1b trial evaluating INO-4201 as a booster for the rVSV-ZEBOV vaccine presented at the 33rd ECCMID. Conducted by Geneva University Hospitals, the trial demonstrated that INO-4201 was well tolerated and generated a robust immune response. Preliminary data indicated that 100% of participants exhibited increased humoral responses, with significant antibody titer boosts observed after vaccination. Geometric mean titers rose markedly after booster administration, indicating potential effectiveness against Zaire ebolavirus. These developments position INO-4201 as a crucial addition to strategies against Ebola Virus Disease, highlighting its significance in public health initiatives against infectious diseases.
INOVIO (NASDAQ: INO) announced that an abstract for its DNA vaccine candidate INO-4201 has been accepted for presentation at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on April 16, 2023. This Phase 1b trial focuses on the vaccine as a booster for the rVSV-ZEBOV (Ervebo) Ebola vaccine. Lead investigator Dr. Angela Huttner will present new humoral and cellular response data during a late-breaking trial session. The trial, involving 46 participants, evaluated the safety, tolerability, and immunogenicity of INO-4201, which targets the Zaire Ebola virus and aims to enhance immune response against various ZEBOV strains. This research is significant as Ebola remains a critical health threat with ongoing outbreaks.
INOVIO (NASDAQ: INO) announced on April 3, 2023, an equity grant to its new Senior Vice President of Regulatory Affairs under the 2022 Inducement Plan. The Compensation Committee approved the award of 45,000 restricted stock units (RSUs) and options for 70,000 shares with a grant date of March 31, 2023. RSUs will vest over three years, while stock options have an exercise price of $0.82, matching the closing stock price on the grant date. The options will vest in phases, contingent on the employee's continued employment. This initiative aligns with INOVIO’s focus on developing DNA medicines against HPV-associated diseases and cancer.
INOVIO (NASDAQ: INO), a biotechnology firm focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced that Jacqueline Shea, Ph.D., CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 10:40 AM ET.
Dr. Shea and the management team will engage in one-on-one meetings with investors. A webcast of the presentation will be available on the INOVIO Investor Relations Events page, with a replay accessible for 90 days post-event. INOVIO's innovative approach includes using the CELLECTRA® device to generate immune responses against targeted health threats.
FAQ
What is the current stock price of Inovio Pharmaceuticals (INO)?
What is the market cap of Inovio Pharmaceuticals (INO)?
What is Inovio Pharmaceuticals' primary focus?
What is INO-3107?
What is the CELLECTRA® device?
Who are some of Inovio’s key partners?
What financial outlook has Inovio projected?
What is INO-3112?
How does Inovio's DNA medicines platform work?
What are some of Inovio’s recent achievements?
Where can I find more financial information about Inovio?